Business
BioRestorative Announces Closing of $5.0 Million Public Offering
MELVILLE, N.Y., Feb. 13, 2026 (GLOBE NEWSWIRE) -- BioRestorative Therapies, Inc. (“BioRestorative”, “BRTX” or the “Company”) (NASDAQ:BRTX), a late stage clinical regenerative medicine innovator focused on stem cell-based therapies and products, today announced the closing of its previously announced public offering of 14,285,715 shares of common stock (or pre-funded warrants in lieu thereof) and warrants to purchase up to 14,285,715 shares of common stock, at a combined public offering price of
About this update from Biorestorative Therapies, Inc.
[{"type":"image","alt":"BioRestorative Therapies, Inc","displaySize":"","headline":null,"caption":"BioRestorative Therapies, Inc","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":122,"url":"https://media.zenfs.com/en/globenewswire.com/681a8d8fe6df06a5512b4bdd3f27c992"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/XBsy.n130Az83pQRRSvCjg--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTE3MTtjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/681a8d8fe6df06a5512b4bdd3f27c992","width":300,"height":122}},"lazy":false},{"type":"text","content":"MELVILLE, N.Y., Feb. 13, 2026 (GLOBE NEWSWIRE) -- BioRestorative Therapies, Inc. (“BioRestorative”, “BRTX” or the “Company”) (NASDAQ:BRTX), a late stage clinical regenerative medicine innovator focused on stem cell-based therapies and products, today announced the closing of its previously announced public offering of 14,285,715 shares of common stock (or pre-funded warrants in lieu thereof) and warrants to purchase up to 14,285,715 shares of common stock, at a combined public offering price of $0.35 per share (or pre-funded warrant in lieu thereof) and accompanying warrants. The warrants have an exercise price of $0.35 per share, are immediately exercisable and will expire five years from the date of issuance.","length":720,"tagName":"p"},{"type":"text","content":"Rodman & Renshaw LLC acted as the exclusive placement agent for the offering.","length":81,"tagName":"p"},{"type":"text","content":"The gross proceeds to the Company from the offering were approximately $5.0 million, before deducting the placement agent’s fees and other offering expenses payable by the Company. The Company intends to use the net proceeds from this offering for its clinical trials with respect to BRTX-100, pre-clinical research and development with respect to its ThermoStem Program, the development of its commercial biocosmeceuticals platform and for general corporate purposes and working capital.","length":488,"tagName":"p"},{"type":"text","content":"A registration statement on Form S-1, as amended (File No. 333-293322), relating to the offering was declared effective by the Securities and Exchange Commission (the “SEC”) on February 11, 2026. The offering was made only by means of a prospectus forming part of the effective registration statement relating to the offering. A final prospectus relating to the of...